Anyone know what a Rebel insulin pump is? (see bold below)
In diabetes, the business delivered solid double digit results on a constant currency basis despite the economic headwinds. These results also reflect the team’s work in successfully managing the Quick-Set field action. We reached over 158,000 patients with replacement products within the first few days of the recall. Additionally, the continued success of continuous glucose monitoring and solid insulin pump sales in this economic environment further validated the value of our market leading technology. This quarter, we also extended our lead as the only company with a proprietary CGM sensor augmented pump on the market by launching the Veo insulin pump in the UK and Ireland. Veo is a significant step forward as the first semi-closed loop product which features a low glucose suspend function that automatically shuts down insulin delivery when a patient’s glucose levels are trending dangerously low, and we’re planning to launch it most international markets later this quarter.
In the US, we’re also very excited about our pipeline and remain on target with plans to launch our Rebel insulin pump later this quarter and our patch and next generation durable pumps in fiscal 2011. These innovations will extend the most complete and comprehensive line of sensor augmented therapy options available on the market.